Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

Franck E. Nicolini, H. Jean Khoury, Luke Akard, Delphine Rea, Hagop Kantarjian, Michele Baccarani, Janis Leonoudakis, Adam Craig, Annie Claude Benichou, Jorge Cortes

Research output: Contribution to journalLetter

16 Scopus citations
Original languageEnglish (US)
Pages (from-to)e78-e79
JournalHaematologica
Volume98
Issue number7
DOIs
StatePublished - Jul 2013

Keywords

  • Advanced chronic myeloid leukemia
  • Dasatinib
  • Homoharringtonine
  • Imatinib
  • Nilotinib
  • Omacetaxine
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Hematology

Cite this

Nicolini, F. E., Khoury, H. J., Akard, L., Rea, D., Kantarjian, H., Baccarani, M., Leonoudakis, J., Craig, A., Benichou, A. C., & Cortes, J. (2013). Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica, 98(7), e78-e79. https://doi.org/10.3324/haematol.2012.083006